KENNEDY LEWIS MANAGEMENT LP - 02 Jun 2022 Form 4 Insider Report for RAPID MICRO BIOSYSTEMS, INC. (RPID)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
06 Jun 2022, 19:45:43 UTC
Prior SEC filing
01 Jun 2022
Next SEC filing
22 Aug 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
KENNEDY LEWIS MANAGEMENT LP, By: KLM GP LLC, its general partner, Name: /s/ Anthony Pasqua, Title: Chief Operating Officer

Key filing fact

KENNEDY LEWIS MANAGEMENT LP filed Form 4 for RAPID MICRO BIOSYSTEMS, INC. (RPID) on 06 Jun 2022.

Key facts

  • This page summarizes KENNEDY LEWIS MANAGEMENT LP's Form 4 filing for RAPID MICRO BIOSYSTEMS, INC. (RPID).
  • 4 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 06 Jun 2022, 19:45.

Change

  • Previous filing in this sequence was filed on 01 Jun 2022.
  • Current net transaction value: +$283,597.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RPID transaction

Common Stock

Purchase

Transaction value
$20,755
Shares
+4,162
Change %
+0.21%
Price
$4.99
Shares after
2,014,839
Date
02 Jun 2022
Ownership
See Footnotes
Footnotes
F1, F2, F3, F4, F5
RPID transaction

Common Stock

Purchase

Transaction value
$29,612
Shares
+5,938
Change %
+0.21%
Price
$4.99
Shares after
2,875,092
Date
02 Jun 2022
Ownership
See Footnotes
Footnotes
F1, F3, F4, F5, F6
RPID transaction

Common Stock

Purchase

Transaction value
$96,100
Shares
+20,602
Change %
+1%
Price
$4.66
Shares after
2,035,441
Date
03 Jun 2022
Ownership
See Footnotes
Footnotes
F2, F3, F4, F5, F7
RPID transaction

Common Stock

Purchase

Transaction value
$137,130
Shares
+29,398
Change %
+1%
Price
$4.66
Shares after
2,904,490
Date
03 Jun 2022
Ownership
See Footnotes
Footnotes
F3, F4, F5, F6, F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares of Common Stock of Rapid Micro Biosystems, Inc. (the "Issuer") were sold in multiple transactions at prices ranging from $4.965 to $5, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in footnotes (1) and (7) to this Form 4.

Footnote F2

These securities of the Issuer are held directly by Kennedy Lewis Capital Partners Master Fund II LP ("Master Fund II", and together with Master Fund III, as defined below, the "Funds").

Footnote F3

Kennedy Lewis Management LP (the "Adviser") acts as investment adviser to the Funds. KLM GP LLC ("KLM") is the general partner of the Adviser. Kennedy Lewis Investment Management LLC ("Kennedy Lewis") is the owner and control person of KLM. David Chene and Darren Richman are the managing members and control persons of Kennedy Lewis. Each of the Adviser, KLM and Kennedy Lewis may be deemed to exercise voting and investment power over and thus may be deemed to beneficially own the securities of the Issuer held by each of the Funds due to their relationship with the Funds. Kennedy Lewis GP II LLC ("Fund II GP") is the general partner of Master Fund II. Kennedy Lewis Investment Holdings II LLC ("Holdings II") is the managing member of Fund II GP. David Chene and Darren Richman are the managing members of Holdings II. Each of Fund II GP and Holdings II may be deemed to exercise voting

Footnote F4

(Continued from footnote 3) and investment power over and thus may be deemed to beneficially own the securities of the Issuer held by Master Fund II due to their relationship with Master Fund II. Kennedy Lewis GP III LLC ("Fund III GP") is the general partner of Master Fund III. Holdings II is the managing member of Fund III GP. David Chene and Darren Richman are the managing members of Holdings II. Each of Fund III GP and Holdings II may be deemed to exercise voting and investment power over and thus may be deemed to beneficially own the securities of the Issuer held by Master Fund III due to their relationship with Master Fund III. David Chene and Darren Richman, in their capacities as managing members of Kennedy Lewis, and managing members of Holdings II, may be deemed to exercise voting and investment power over and thus may be deemed to beneficially own the securities held by each of the Funds due to their relationships with the Funds.

Footnote F5

For purposes of Section 16 of the Securities Exchange Act of 1934, each of the Adviser, KLM, Kennedy Lewis, Fund II GP, Holdings II, Fund III GP, David Chene and Darren Richman disclaims beneficial ownership of the securities of the Issuer held directly by the Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of the Adviser, KLM, Kennedy Lewis, Fund II GP, Holdings II, Fund III GP, David Chene or Darren Richman is the beneficial owner of such securities for purposes of Section 16 or any other purpose.

Footnote F6

These securities of the Issuer are held directly by Kennedy Lewis Capital Partners Master Fund III LP ("Master Fund III").

Footnote F7

The price reported in Column 4 is a weighted average price. These shares of Common Stock of the Issuer were sold in multiple transactions at prices ranging from $4.54 to $4.8, inclusive.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .